Indivior PLC Stock Forecast for 2023 - 2025 - 2030

Updated on 06/04/2023

Stock Rating
14
Price Target
£4.74
Consensus
Outperform
Downside
-97.14%
Analysts
1
Stock Rating
14
Downside
-97.14%
Analysts
1
Price Target
£4.74

Indivior PLC Stock Forecast and Price Target

The average target price set lately by experts for Indivior PLC to reach by the end of the year is £4.74, which would imply a potential downside of approximately -97.14 percent from the previous closing price if it were to be achieved. This prediction is based on a high estimate of £5.09 and a low estimate of £3.93. Even if you are not interested in INDV stock, you should still be aware of its competitors.

£4.74

-97.14% Downside

Buy
Buy

Indivior PLC Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Indivior PLC's Price has decreased from £2.13 to £1.67 – a 21.74% drop! The next year looks promising for Indivior PLC, with analysts predicting Fair Value of £2.09 – an increase of 25.46%. Over the next nine years, experts anticipate that Indivior PLC's Fair Value will grow at a rate of 26.02%.

2022 Fair Value Forecast
£2.09
2023 Fair Value Forecast
£2.87
2024 Fair Value Forecast
£1.88
2025 Fair Value Forecast
£1.91
2026 Fair Value Forecast
£2.06
2027 Fair Value Forecast
£2.36
2028 Fair Value Forecast
£2.19
2029 Fair Value Forecast
£2.10
2030 Fair Value Forecast
£2.10
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LLY Stock Forecast Eli Lilly & Co Outperform 14
$442.33 Buy/Sell $333.19 -9.57%
PFE Stock Forecast Pfizer Inc Outperform 3
$38.36 Buy/Sell $47.96 37.25%
AZN Stock Forecast AstraZeneca PLC Buy 8
£11.75k Buy/Sell £153.20 -98.67%
GMAB Stock Forecast Genmab A/S Outperform 16
kr3.00k Buy/Sell kr2.84k -8.24%
ARGX Stock Forecast argenx Buy 4
358.10€ Buy/Sell 0.00€ -0.31%

Indivior PLC Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Indivior PLC's Revenue has grown, increasing from £785.00M to £791.00M – a growth of 0.76%. The next year, 0 experts forecast that Indivior PLC's Revenue will decrease by 5.02%, reaching £751.27M. In 2030, professionals predict that Indivior PLC's Revenue will decrease by 5.03%, reaching £751.19M.

2022 Rev Forecast
£0.75B
2023 Rev Forecast
£0.77B
2024 Rev Forecast
£0.73B
2025 Rev Forecast
£0.75B
2026 Rev Forecast
£0.75B
2027 Rev Forecast
£0.76B
2028 Rev Forecast
£0.75B
2029 Rev Forecast
£0.75B
2030 Rev Forecast
£0.75B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
TEVA Stock Forecast Teva Pharmaceutical Industries Hold 12
$7.23 Buy/Sell $12.04 38.31%
REC Stock Forecast Recordati Industria Chimica e ... Hold 18
38.68€ Buy/Sell 49.03€ 13.75%
ORNBV Stock Forecast Orion Oyj Hold 14
53.46€ Buy/Sell 34.70€ -25.18%

Indivior PLC Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ITCI Stock Forecast Intra-Cellular Therapies Outperform 10
$61.32 Buy/Sell $68.92 14.16%
HIK Stock Forecast Hikma Pharmaceuticals PLC Outperform 18
£1.80k Buy/Sell £29.33 -98.47%
ALKS Stock Forecast Alkermes Hold 10
$27.11 Buy/Sell $0.00 18.04%

Indivior PLC Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Indivior PLC's Free Cash Flow has grown by 142.36%, rising from £144.00M to £349.00M. According to 0 prominent analysts, Indivior PLC's Free Cash Flow will fall by 47.54% in the next year, reaching £183.09M. By 2030, professionals believe that Indivior PLC's Free Cash Flow will decrease by 35.42%, reaching £225.38M – a concerning trend for the company.

2022 FCF Forecast
£0.18B
2023 FCF Forecast
£0.25B
2024 FCF Forecast
£0.17B
2025 FCF Forecast
£0.23B
2026 FCF Forecast
£0.23B
2027 FCF Forecast
£0.24B
2028 FCF Forecast
£0.22B
2029 FCF Forecast
£0.22B
2030 FCF Forecast
£0.23B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LUN Stock Forecast H. Lundbeck A/S Outperform 18
kr23.88 Buy/Sell kr224.81 716.58%
ALK B Stock Forecast ALK-Abelló A/S Hold 13
kr96.05 Buy/Sell kr3.35k 84.80%
EVT Stock Forecast Evotec Outperform 14
21.71€ Buy/Sell 37.33€ 52.00%

Indivior PLC Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Indivior PLC's Net Income has grown from £134.00M to £205.00M – a 52.99% increase. For the next year, 0 analysts project Indivior PLC's Net Income to drop by 51.29%, reaching £99.86M. By 2030, professionals believe that Indivior PLC's Net Income will decrease by 36.85%, reaching £129.46M – a concerning trend for the company.

2022 NI Forecast
£0.10B
2023 NI Forecast
£0.14B
2024 NI Forecast
£0.10B
2025 NI Forecast
£0.14B
2026 NI Forecast
£0.13B
2027 NI Forecast
£0.14B
2028 NI Forecast
£0.12B
2029 NI Forecast
£0.13B
2030 NI Forecast
£0.13B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ALM Stock Forecast Almirall Outperform 16
8.56€ Buy/Sell 14.28€ 63.55%
CLIN Stock Forecast Clinigen Group Outperform 18
£9.25 Buy/Sell £7.78 75.89%
FAE Stock Forecast Faes Farma Hold 18
3.36€ Buy/Sell 4.20€ 25.00%

Indivior PLC EBITDA Forecast for 2023 - 2025 - 2030

Indivior PLC's EBITDA has decreased In the last two years, from £214.00M to £198.00M – a 7.48% drop. For next year, analysts predict EBITDA of £207.17M, which would mean an increase of 4.63%. Over the next nine years, experts predict that Indivior PLC's EBITDA will grow at a rate of 3.34%.

2022 EBITDA Forecast
£0.21B
2023 EBITDA Forecast
£0.25B
2024 EBITDA Forecast
£0.19B
2025 EBITDA Forecast
£0.20B
2026 EBITDA Forecast
£0.20B
2027 EBITDA Forecast
£0.22B
2028 EBITDA Forecast
£0.21B
2029 EBITDA Forecast
£0.20B
2030 EBITDA Forecast
£0.20B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
VEC Stock Forecast Vectura Group Hold 14
£165.00 Buy/Sell £1.41 -98.88%
PHM Stock Forecast Pharma Mar Outperform 13
33.64€ Buy/Sell 0.00€ 144.35%
COPN Stock Forecast Cosmo Pharmaceuticals N.V. Buy 12
CHF56.10 Buy/Sell CHF0.00 65.54%

Indivior PLC EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Indivior PLC's EBIT has seen a drop from £202.00M to £186.00M – a 7.92% decrease. In the next year, analysts believe that EBIT will reach £200.99M – an increase of 8.06%. For the next nine years, the forecast is for EBIT to grow by 6.72%.

2022 EBIT Forecast
£0.20B
2023 EBIT Forecast
£0.25B
2024 EBIT Forecast
£0.18B
2025 EBIT Forecast
£0.19B
2026 EBIT Forecast
£0.20B
2027 EBIT Forecast
£0.22B
2028 EBIT Forecast
£0.20B
2029 EBIT Forecast
£0.20B
2030 EBIT Forecast
£0.20B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ZEAL Stock Forecast Zealand Pharma A/S Outperform 8
kr117.00 Buy/Sell kr241.83 70.94%
MOR Stock Forecast MorphoSys Outperform 6
24.45€ Buy/Sell 40.70€ 41.10%
VNDA Stock Forecast Vanda Pharmaceuticals Hold 0
$5.90 Buy/Sell $24.00 69.49%

Indivior PLC EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Indivior PLC's EPS has decreased from £0.23 to £0.18 – a 21.74% drop! The next year looks promising for Indivior PLC, with analysts predicting EPS of £0.23 – an increase of 25.46%. Over the next nine years, experts anticipate that Indivior PLC's EPS will grow at a rate of 26.02%.

2022 EPS Forecast
£0.23
2023 EPS Forecast
£0.31
2024 EPS Forecast
£0.20
2025 EPS Forecast
£0.21
2026 EPS Forecast
£0.22
2027 EPS Forecast
£0.26
2028 EPS Forecast
£0.24
2029 EPS Forecast
£0.23
2030 EPS Forecast
£0.23
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
NasdaqGS:BDSI Stock Forecast BioDelivery Sciences Internati... - 11
$5.59 Buy/Sell $10.00 78.89%
BSLN Stock Forecast Basilea Pharmaceutica Buy 6
CHF42.26 Buy/Sell CHF87.60 72.74%
AMRX Stock Forecast Amneal Pharmaceuticals Outperform 16
$2.55 Buy/Sell $0.00 174.51%